Braf V600 Mutation Positive Melanoma Therapeutics
1. Mekinist patent expiration
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Me...
MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(4 years from now) | |
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(4 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(7 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(6 years from now) | |
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(6 months ago) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(6 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(6 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(6 years from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(1 year, 10 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(29 days ago) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(6 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(5 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(5 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Feb, 2034
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Dosage: TABLET; SOLUTION
More Information on Dosage
MEKINIST family patents
